IL6R and cancer: We furthermore show that IL-6 and M-CSF are strong drivers of increased abundance of immune incompetent CD14+ DC3s in the context of cancer and show that pharmacological inhibition of the IL-6R and CSF1R has potential to improve immunotherapy.